Tuesday, February 4, 2020

Tepezza™ is first and only FDA-approved treatment for Thyroid Eye Disease. Approval marks fourth FDA-approved product containing technologies created at The Lundquist Institute.

LOS ANGELES — The U.S. Food and Drug Administration (FDA) approved Tepezza™ for the treatment of Thyroid Eye Disease (TED) on January 21, marking the fourth FDA-approved product containing technologies pioneered at The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), in the last 17 years—and the third in the last five years.

Wednesday, January 29, 2020

Longtime business development executive to oversee incubator facilities and biotech park planning

LOS ANGELES – The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), has promoted Keith Bronson Hoffman, PhD to Senior Vice President of Business Development and Technology Transfer.

Thursday, January 23, 2020

The Lundquist Institute research offers lessons for communities from California to Australia

Investigator(s): Merritt Schreiber

LOS ANGELES — An investigator from The Lundquist Institute has demonstrated a way to limit the effects of post-traumatic stress disorder in those affected by wildfires through early intervention and triage using a web-based app, providing valuable insight for medical professionals and first responders dealing with the aftermath of another devastating fire season.

Wednesday, January 22, 2020

Abstaining from cocaine use can help HIV-positive people with cognition 

Investigator(s): Matthew Wright, PhD

LOS ANGELES — A new study from The Lundquist Institute shows that cocaine use exacerbates memory loss and other neuropsychological impairments among people with HIV, providing new insight into the effects of cocaine and more information to better treat HIV-positive individuals. 

Monday, January 13, 2020

New study from The Lundquist Institute can help stop the spread of superbugs

LOS ANGELES — A new study from The Lundquist Institute shows a reliable, repeatable way to reduce the unnecessary use of antibiotics in emergency departments and urgent care centers. Overusing antibiotics does not help patients, wastes money, and more importantly is accelerating the epidemic of drug-resistant bacteria—or “superbugs.”

Tuesday, January 7, 2020

Study from The Lundquist Institute finds sub-dissociative doses useful for acute flare-ups

Investigator(s): David Tanen, PhD

LOS ANGELES — A study from The Lundquist Institute shows that modest doses of ketamine can effectively treat acute exacerbations of chronic pain, providing physicians with another proven option aside from addictive opioids, which have devastated communities and resulted in thousands of early deaths in recent years.

Thursday, December 19, 2019

Longtime education executive will oversee media and government relations

LOS ANGELES – The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), has promoted Jody Spillane to Senior Vice President of Public Affairs.

Friday, December 13, 2019

Chlebowski presented findings at San Antonio Breast Cancer Symposium on Friday

Investigator(s): Rowan T Chlebowski, MD, PhD

SAN ANTONIO — In a Friday morning presentation at the San Antonio Breast Cancer Symposium, one of the biggest international conferences on breast cancer,
The Lundquist Institute investigator Dr. Rowan Chlebowski shared new data that could help dramatically reduce the risk of breast cancer in postmenopausal women who are on hormone therapy.

Tuesday, December 3, 2019

Study from The Lundquist Institute shows viable alternative to intravenous treatment

Investigator(s): David Tanen, PhD

LOS ANGELES — Findings from a study from The Lundquist Institute could reduce a major source of headaches for severe migraine sufferers: hospital visits.

Many people suffering from migraine headaches can control them at home through common oral medications such as sumatriptan, but there’s a substantial population that requires professional treatment to mitigate the unbearable pain. For the last four decades, that treatment has consisted of the insertion of an intravenous line to pump medicine—most commonly prochlorperazine—directly into the patient’s bloodstream.

Tuesday, November 19, 2019

The Lundquist Institute investigator Dr. Matthew Budoff presented results at AHA conference

Study shows The Lundquist Institute is top-tier venue for pharmaceutical research

Investigator(s): Matthew Budoff, MD

PHILADELPHIA — Findings from a new study provide a promising pathway toward reducing the impact of heart disease, as the data shows that Vascepa, a drug derived from omega-3 oils that is commonly used to treat hypertriglyceridemia, a disease that causes elevated fat levels in blood, also reduces the progression of heart disease.